Physician profile
Joseph A Catania
NPI 1194710806
$3,956.58
in general payments reported to CMS, 2019-2025
21 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $24.05 · 2021: $83.17 · 2022: $1,025 · 2023: $677 · 2024: $791 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,079.04 | 2022-2023 | Intracept |
| Vertiflex, INC. | $667.86 | 2019 | |
| Boston Scientific Corporation | $557.86 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Abbott Laboratories | $372.95 | 2019-2025 | Eterna |
| Vertos Medical, INC. | $288.39 | 2022-2023 | Mild Device Kit |
| Stryker Corporation | $225.50 | 2024-2025 | Mild Device Kit |
| Medtronic, INC. | $131.64 | 2024-2025 | Inceptiv |
| Spr Therapeutics, INC | $125.85 | 2023-2024 | Sprint Pns System |
| Nevro Corp. | $105.31 | 2019-2023 | Senza |
| Saluda Medical Americas, INC. | $102.57 | 2024 | Evoke |
| Collegium Pharmaceutical, INC. | $54.18 | 2023-2024 | Xtampza |
| Nalu Medical, INC. | $49.55 | 2024 | Nalu Neurostimulation System |
| Globus Medical, INC. | $47.15 | 2025 | Senza |
| Abbvie INC. | $33.49 | 2023 | Ubrelvy, Qulipta |
| Scilex Pharmaceuticals INC. | $20.23 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.53 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.58 | 2023 | Lyvispah |
| Takeda Pharmaceuticals U.S.A., INC. | $16.23 | 2024 | Gattex |
| Teva Pharmaceuticals USA, INC. | $15.59 | 2022 | |
| Fidia Pharma USA INC. | $14.54 | 2022 | |
| Horizon Therapeutics Plc | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Catania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.